Application of substance taking PTPN14 or coding gene thereof as target spot in preparation of product for treating endovascular hyperplasia

By inhibiting PTPN14 gene expression or protein activity, and using biological materials such as double-stranded RNA, the problem of endometrial hyperplasia is solved, effectively inhibiting the proliferation and migration of smooth muscle cells, improving vascular function, and solving the blood vessels caused by endometrial hyperplasia in vascular Incomplete functionality problem.

CN119055768APending Publication Date: 2024-12-03TIANJIN MEDICAL UNIV
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202310641690.8
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2023-06-01
Publication Date
2024-12-03

AI Technical Summary

Technical Problem

The prior art is difficult to effectively inhibit endovascular hyperplasia, resulting in vascular insufficiency and affect cardiovascular health.

Method used

By inhibiting PTPN14 gene expression or protein activity, biological materials such as double-stranded RNA molecules, DNA molecules, recombinant vectors are prepared to treat or prevent vascular endometrial hyperplasia and inhibit the proliferation and migration of smooth muscle cells.

Benefits of technology

It effectively inhibits the proliferation of vascular endometrium, reduces the migration and proliferation of smooth muscle cells, slows down the progression of vascular stenosis, and improves vascular function.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure HDA0004261706780000011
    Figure HDA0004261706780000011
  • Figure HDA0004261706780000021
    Figure HDA0004261706780000021
  • Figure HDA0004261706780000031
    Figure HDA0004261706780000031
Patent Text Reader

Abstract

The invention discloses application of a substance taking PTPN14 or an encoding gene thereof as a target spot in preparation of a product for treating vascular intimal hyperplasia. The invention belongs to the field of biological medicines, and particularly relates to application of a substance taking PTPN14 or an encoding gene thereof as a target spot in preparation of a product for treating vascular intimal hyperplasia. Experiments prove that the substance for inhibiting PTPN14 expression in cells or the substance for inhibiting PTPN14 activity in cells can effectively inhibit proliferation, migration and / or invasion of smooth muscle cells and inhibit growth of vascular smooth muscles, and can be used for treating vascular intimal hyperplasia or / and preventing vascular intimal hyperplasia.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention belongs to the field of biomedicine, and specifically relates to the application of a substance targeting PTPN14 or its encoding gene in the preparation of a product for treating vascular intimal hyperplasia. Background Art

[0002] For a long time, the prevalence of cardiovascular diseases has remained high, and the number of deaths caused by them has increased year by year. Cardiovascular diseases are a type of circulatory system disease, including coronary heart disease, peripheral artery disease, cardiomyopathy and other diseases involving heart and vascular lesions. Among them, coronary heart disease, also known as coronary artery disease, is the most common cardiovascular disease, and atherosclerosis is the main cause of coronary artery disease. Plaque deposition in the coronary artery causes narrowing of the arterial lumen, resulting in obstruction of blood supply to the heart and causing myocardial ischemia. Clinically, treatment methods such as angioplasty and bypass grafting can be used to restore blood flow, but it will inevitably damage the intima layer of the blood vessel. The smooth muscle cells in the media layer are exposed to pathological stimuli such as blood flow shear force, chemokines and cytokines, and migrate and proliferate under the intima, which can induce adverse vascular remodeling. Vascular dysfunction caused by restenosis is seriously harmful, and it is crucial to clarify the mechanism of action of smooth muscle cells in pathological remodeling.

[0003] Vascular smooth muscle cells (VSMCs) are located in the media layer of normal blood vessels and play an important role in maintaining physiological functions such as vascular elasticity, normal caliber, blood flow distribution and vasoconstriction. Smooth muscle cells are involved in the occurrence and progression of cardiovascular diseases such as atherosclerosis, hypertension, aneurysm, aortic dissection, and pulmonary hypertension. Vascular smooth muscle cells have phenotypic plasticity. When blood vessels are damaged, vascular smooth muscle cells located in the media layer migrate to the subintima and undergo pathological proliferation, thereby causing neointimal regeneration in the vascular lumen and causing vascular stenosis. In this pathological process, smooth muscle cells undergo phenotypic transformation, migration and excessive proliferation, and the state of the extracellular matrix also changes, hyaluronic acid gradually decreases, and collagen fibers are deposited. The phenotypic transformation process of smooth muscle cells changes from a fully differentiated state to a dedifferentiated state, which is manifested by the decrease in the expression of smooth muscle cell contractile markers α-smooth muscle actin (α-SMA), smooth muscle 22α-protein (SM22), calmodulin (CNN1), and smooth muscle myosin heavy chain (SMMHC), and the increase in the expression of secretory markers vimentin, matrix Gla protein (MGP), and osteopontin. In the early stages of this process, it is generally considered to be a reversible process. In addition, the content of endoplasmic reticulum, ribosomes and Golgi bodies in the cells increases, and the content of matrix metalloproteinases (MMPs) increases significantly, which enables the cells to synthesize and secrete a large amount of extracellular matrix, accompanied by an increase in the migration and proliferation ability of smooth muscle cells.

[0004] PTPN14, also known as Pez, PTP36, and PTPD2, is a member of the non-transmembrane tyrosine phosphatases and belongs to the classic phosphotyrosine (pY)-specific phosphatases. It was first discovered in normal human breast tissue in 1995 and is widely expressed in skeletal muscle, kidney, lung, placenta and other tissues. PTPN14 has an N-terminal FERM domain (Band 4.1, ezrin, radixin, moesin) associated with the cytoskeleton, an intermediate linker region PPxY domain containing an acidic region that can interact with other proteins containing a putative SH3 domain, and a C-terminal conserved PTP domain involved in catalytic phosphorylation. The function of PTPN14 in smooth muscle cells and its role in intimal hyperplasia are still unclear. Therefore, this study aims to explore the biological function of PTPN14 in smooth muscle cells and its mechanism of action in regulating the process of intimal regeneration, and to find therapeutic targets for the prevention and treatment of intimal hyperplasia. Summary of the invention

[0005] A technical problem to be solved by the present invention is how to inhibit intimal hyperplasia.

[0006] In order to solve the above technical problems, the present invention provides any of the following uses of a substance for inhibiting the expression of PTPN14 in cells and a substance for inhibiting the activity of PTPN14 in cells:

[0007] 1. Use of substances that inhibit PTPN14 gene expression in the preparation of products for treating and / or preventing vascular intimal hyperplasia.

[0008] 2. Use of substances that inhibit PTPN14 gene expression in the preparation of products that inhibit smooth muscle cell proliferation and / or migration.

[0009] 3. Use of substances that inhibit the activity of PTPN14 protein in the preparation of products for treating and / or preventing vascular intimal hyperplasia.

[0010] 4. Use of substances that inhibit the activity of PTPN14 protein in the preparation of products that inhibit smooth muscle cell proliferation and / or migration.

[0011] 5. Use of substances that reduce the content of PTPN14 protein in the preparation of products for treating and / or preventing vascular intimal hyperplasia.

[0012] 6. Use of substances that reduce PTPN14 protein content in the preparation of products that inhibit smooth muscle cell proliferation and / or migration.

[0013] In the above application, the substance that inhibits PTPN14 gene expression or the substance that inhibits PTPN14 protein activity can be any of the following biological materials:

[0014] 1) a double-stranded RNA molecule, a modified substance thereof, or a pharmaceutically acceptable salt thereof;

[0015] B1) producing a DNA molecule of the double-stranded RNA molecule described in 1);

[0016] B2) an expression cassette containing the DNA molecule described in B1);

[0017] B3) a recombinant vector containing the DNA molecule described in B1);

[0018] B4) a recombinant vector containing the expression cassette described in B2);

[0019] B5) a recombinant microorganism containing the DNA molecule described in B1);

[0020] B6) a recombinant microorganism containing the expression cassette described in B2);

[0021] B7) a recombinant microorganism containing the recombinant vector described in B3);

[0022] B8) a recombinant microorganism containing the recombinant vector described in B4);

[0023] B9) a transgenic animal cell line containing the DNA molecule described in B1);

[0024] B10) a transgenic animal cell line containing the expression cassette described in B2);

[0025] B11) a transgenic animal cell line containing the recombinant vector described in B3);

[0026] B12) a transgenic animal cell line containing the recombinant vector described in B4);

[0027] B13) A transgenic plant cell line containing the DNA molecule described in B1).

[0028] In the above application, the substance that inhibits PTPN14 gene expression or the substance that inhibits PTPN14 protein activity is a double-stranded RNA molecule, and the double-stranded RNA molecule can be siPTPN14 (Santa Cruz Biotechnology, catalog number: sc-62777).

[0029] The control siRNA and target siPTPN14 were purchased from Santa Cruz Biotechnology (control siNC catalog number: sc-37007; siPTPN14 catalog number: sc-62777).

[0030] In the above application, the recombinant microorganism may be a recombinant lentivirus expressing the siRNA or shRNA.

[0031] In the above applications, the cells may be mammalian cells, such as human or mouse cells.

[0032] In the above application, the PTPN14 may be PTPN14 of mammalian cells, such as human PTPN14 or mouse PTPN14.

[0033] In the above application, the smooth muscle cells are human smooth muscle cells or mouse smooth muscle cells.

[0034] The smooth muscle cells may be vascular smooth muscle cells.

[0035] The present invention also provides a product for treating or / and preventing intimal hyperplasia, wherein the product contains any one of the following biological materials:

[0036] 1) a double-stranded RNA molecule, a modified substance thereof, or a pharmaceutically acceptable salt thereof;

[0037] B1) producing a DNA molecule of the double-stranded RNA molecule described in 1);

[0038] B2) an expression cassette containing the DNA molecule described in B1);

[0039] B3) a recombinant vector containing the DNA molecule described in B1);

[0040] B4) a recombinant vector containing the expression cassette described in B2);

[0041] B5) a recombinant microorganism containing the DNA molecule described in B1);

[0042] B6) a recombinant microorganism containing the expression cassette described in B2);

[0043] B7) a recombinant microorganism containing the recombinant vector described in B3);

[0044] B8) a recombinant microorganism containing the recombinant vector described in B4);

[0045] B9) a transgenic animal cell line containing the DNA molecule described in B1);

[0046] B10) a transgenic animal cell line containing the expression cassette described in B2);

[0047] B11) a transgenic animal cell line containing the recombinant vector described in B3);

[0048] B12) a transgenic animal cell line containing the recombinant vector described in B4);

[0049] B13) A transgenic plant cell line containing the DNA molecule described in B1).

[0050] The present invention also provides a product for inhibiting smooth muscle cell proliferation and / or migration, wherein the product contains any one of the following biological materials:

[0051] 1) a double-stranded RNA molecule, a modified substance thereof, or a pharmaceutically acceptable salt thereof;

[0052] B1) producing a DNA molecule of the double-stranded RNA molecule described in 1);

[0053] B2) an expression cassette containing the DNA molecule described in B1);

[0054] B3) a recombinant vector containing the DNA molecule described in B1);

[0055] B4) a recombinant vector containing the expression cassette described in B2);

[0056] B5) a recombinant microorganism containing the DNA molecule described in B1);

[0057] B6) a recombinant microorganism containing the expression cassette described in B2);

[0058] B7) a recombinant microorganism containing the recombinant vector described in B3);

[0059] B8) a recombinant microorganism containing the recombinant vector described in B4);

[0060] B9) a transgenic animal cell line containing the DNA molecule described in B1);

[0061] B10) a transgenic animal cell line containing the expression cassette described in B2);

[0062] B11) a transgenic animal cell line containing the recombinant vector described in B3);

[0063] B12) a transgenic animal cell line containing the recombinant vector described in B4);

[0064] B13) A transgenic plant cell line containing the DNA molecule described in B1).

[0065] In the above applications, the product may be a medicine or a vaccine.

[0066] The drug for treating vascular intimal hyperplasia or / and preventing vascular intimal hyperplasia or / and inhibiting smooth muscle cell proliferation and / or migration provided by the present invention contains the double-stranded RNA molecule, its modified substance, or its pharmaceutically acceptable salt.

[0067] The dosage form of the above-mentioned drug can be tablets, capsules, dripping pills, pills, powders, solutions, suspensions, emulsions, granules, liposomes, transdermal agents, buccal tablets, suppositories or lyophilized powder injections.

[0068] In the above, the active ingredient of the drug of the product for treating intimal hyperplasia, or / and preventing intimal hyperplasia, or / and inhibiting smooth muscle cell proliferation and / or migration may be the double-stranded RNA molecule, its modified product, or a pharmaceutically acceptable salt thereof, and the active ingredient of the drug for treating intimal hyperplasia, or / and preventing intimal hyperplasia, or / and inhibiting smooth muscle cell proliferation and / or migration may also contain other substances, and those skilled in the art may determine the other substances according to the effects of the drug for treating intimal hyperplasia, or / and preventing intimal hyperplasia, or / and inhibiting smooth muscle cell proliferation and / or migration.

[0069] In the above, the drug for treating intimal hyperplasia or / and preventing intimal hyperplasia or / and inhibiting smooth muscle cell proliferation and / or migration may contain a suitable carrier or excipient in addition to the double-stranded RNA molecule, its modified substance, or its pharmaceutically acceptable salt. The carrier material here includes but is not limited to water-soluble carrier materials (such as polyethylene glycol, polyvinyl pyrrolidone, organic acid, etc.), poorly soluble carrier materials (such as ethyl cellulose, cholesterol stearate, etc.), enteric carrier materials (such as cellulose acetate phthalate and carboxymethyl ethyl cellulose, etc.). Among them, water-soluble carrier materials are preferred. These materials can be made into a variety of dosage forms, including but not limited to tablets, capsules, dripping pills, aerosols, pills, powders, solutions, suspensions, emulsions, granules, liposomes, transdermal agents, buccal tablets, suppositories, freeze-dried powder injections, etc. It can be a common preparation, a sustained-release preparation, a controlled-release preparation, and various microparticle delivery systems. In order to make the unit dosage form into tablets, various carriers known in the art can be widely used. Examples of carriers include diluents and absorbents, such as starch, dextrin, calcium sulfate, lactose, mannitol, sucrose, sodium chloride, glucose, urea, calcium carbonate, kaolin, microcrystalline cellulose, aluminum silicate, etc.; wetting agents and binders, such as water, glycerol, polyethylene glycol, ethanol, propanol, starch paste, dextrin, syrup, honey, glucose solution, acacia paste, gelatin paste, sodium carboxymethylcellulose, shellac, methylcellulose, potassium phosphate, polyvinyl pyrrolidone, etc.; disintegrants. , such as dry starch, alginate, agar powder, brown algae starch, sodium bicarbonate and citric acid, calcium carbonate, polyoxyethylene, sorbitan fatty acid esters, sodium lauryl sulfate, methyl cellulose, ethyl cellulose, etc.; disintegration inhibitors, such as sucrose, tristearate, cocoa butter, hydrogenated oil, etc.; absorption promoters, such as quaternary ammonium salts, sodium lauryl sulfate, etc.; lubricants, such as talc, silicon dioxide, corn starch, stearate, boric acid, liquid paraffin, polyethylene glycol, etc. The tablets can also be further made into coated tablets, such as sugar-coated tablets, film-coated tablets, enteric-coated tablets, or double-layer tablets and multi-layer tablets. In order to make the unit dosage form into a pill, various carriers known in the art can be widely used. Examples of carriers include diluents and absorbents, such as glucose, lactose, starch, cocoa butter, hydrogenated vegetable oil, polyvinyl pyrrolidone, Gelucire, kaolin, talc, etc.; binders, such as gum arabic, tragacanth, gelatin, ethanol, honey, liquid sugar, rice paste or flour paste, etc.; disintegrants, such as agar powder, dry starch, alginate, sodium lauryl sulfate, methyl cellulose, ethyl cellulose, etc. In order to prepare a unit dosage form as a suppository, various carriers known in the art can be widely used. Examples of carriers include, for example, polyethylene glycol, lecithin, cocoa butter, higher alcohols, esters of higher alcohols, gelatin, semi-synthetic glycerides, etc.In order to prepare the unit dosage form into an injectable preparation, such as a solution, emulsion, freeze-dried powder injection and suspension, all diluents commonly used in the art can be used, for example, water, ethanol, polyethylene glycol, 1,3-propylene glycol, ethoxylated isostearyl alcohol, polyoxygenated isostearyl alcohol, polyoxyethylene sorbitol fatty acid esters, etc. In addition, in order to prepare an isotonic injection, an appropriate amount of sodium chloride, glucose or glycerol can be added to the injectable preparation. In addition, conventional cosolvents, buffers, pH regulators, etc. can also be added. In addition, if necessary, colorants, preservatives, spices, flavoring agents, sweeteners or other materials can also be added to the pharmaceutical preparation. The above dosage form can be used for administration by injection, including subcutaneous injection, intravenous injection, intramuscular injection and intracavitary injection, etc.; cavity administration, such as rectal and vaginal; respiratory tract administration, such as nasal; mucosal administration. The above administration route is preferably injection.

[0070] In the above product, the smooth muscle cells are human smooth muscle cells or mouse smooth muscle cells.

[0071] In the above product, the smooth muscle cells may be vascular smooth muscle cells.

[0072] In order to clarify the function of PTPN14 in smooth muscle cells, the expression of PTPN14 was knocked down in vascular smooth muscle cells, and the cells were stimulated with the inducing factor PDGF-BB. The migration and proliferation abilities of smooth muscle cells were evaluated by scratch assay, transwell migration assay and immunofluorescence Ki-67 staining. At the in vivo animal experimental level, a neointimal regeneration model was constructed by performing left common carotid artery guidewire injury surgery on C57BL / 6 mice and smooth muscle-specific PTPN14 knockout mice, in order to explore the differential expression and role of PTPN14 in the neointimal membrane.

[0073] This study confirmed that PTPN14 is enriched in smooth muscle cells with neointimal hyperplasia. PTPN14 upregulated its expression level in response to vascular injury in a mouse guidewire strain model. PTPN14 promotes smooth muscle cell migration, proliferation, and phenotypic transformation, thereby aggravating the process of intimal hyperplasia. This indicates that high expression of PTPN14 can promote the occurrence and development of intimal hyperplasia during injury-mediated vascular remodeling, and inhibiting the expression of PTPN14 can inhibit vascular intimal hyperplasia. BRIEF DESCRIPTION OF THE DRAWINGS

[0074] Figure 1The expression of PTPN14 in the neointimal region is increased. A. HE staining of tissue sections 14 and 21 days after wire-strain surgery on the left common carotid artery of C57BL / 6 mice. The contralateral exposed vessels were used as the control group for tissue sections and HE staining. Scale bar = 50 μm. Immunofluorescence staining of carotid artery tissue sections. PTPN14: red; smooth muscle cell marker α-SMA: green; cell nucleus DAPI: blue; scale bar = 50 μm; B. Statistical analysis of PTPN14 immunofluorescence staining. Data are shown as Mean ± SEM, and statistical differences were analyzed by one-way ANOVA, *p < 0.05, n = 5; C. Samples were collected 14 and 21 days after wire-strain surgery on the left common carotid artery of C57BL / 6 mice. The contralateral exposed vessels were used as the control group. The carotid arteries of two mice in the same treatment group were mixed into one independent lane. Western blot analysis was used to quantitatively detect the expression of PTPN14, α-SMA, SM22, and GAPDH; D Statistical analysis of carotid artery protein PTPN14, α-SMA, and SM22 by Western blot. Data are expressed as Mean ± SEM, and statistical differences were analyzed by one-way ANOVA, *p < 0.05, n = 6.

[0075] Figure 2 Overexpression of PTPN14 aggravates the neointimal process. A. After left common carotid artery guidewire strain surgery, C57BL / 6 mice were infected with PTPN14 overexpression adenovirus (AdPTPN14 group) and control adenovirus (AdNC group) for 14 days, and the right common carotid artery was only exposed and incubated with PTPN14 overexpression adenovirus (Ad PTPN14 group) and control adenovirus (AdNC group) for 14 days. Representative images of HE staining of tissue sections, scale bar = 50μm; B. Statistical analysis of HE tissue sections. Data are presented as Mean ± SEM, and statistical differences were analyzed by one-way ANOVA, *p<0.05, n=5; C. C57BL / 6 mice were infected with PTPN14 overexpression adenovirus (AdPTPN14 group) and control adenovirus (AdNC group) for 14 days after left common carotid artery guidewire strain surgery, and the right common carotid artery was only exposed and incubated with PTPN14 overexpression adenovirus (AdPTPN14 group) and control adenovirus (AdNC group) for 14 days, and immunofluorescence staining of PCNA-positive cells in tissue sections. PCNA: red; smooth muscle cell marker α-SMA: green; cell nucleus DAPI: blue; scale bar = 50 μm; D. Statistical analysis of PCNA immunofluorescence staining of left common carotid artery. Data are presented as Mean ± SEM, and statistical differences were analyzed by one-way ANOVA, *p<0.05, n=5.

[0076] Figure 3 Inhibition of neointimal regeneration by knocking out PTPN14 in smooth muscle cells. SMC- / -Indicates smooth muscle cell PTPN14-specific knockout mice, referred to as gene knockout mice, PTPN14 flox Indicates control mice. A. HE staining of tissue sections 21 days after left common carotid artery wire strain surgery, scale bar = 50 μm; B. Statistical analysis of HE staining of tissue sections. Data are shown as Mean ± SEM, and statistical differences are analyzed by unpaired two-tailed t-test, *p < 0.05, n = 6; C. PCNA immunofluorescence staining of left common carotid artery tissue sections. PCNA: red; smooth muscle cell marker α-SMA: green; cell nucleus DAPI: blue; scale bar = 50 μm; D. Statistical analysis of PCNA immunofluorescence staining. Data are shown as Mean ± SEM, and statistical differences are analyzed by unpaired two-tailed t-test, *p < 0.05, n = 6; E. 21 days after left common carotid artery wire strain surgery in knockout mice and control mice, protein immunoblotting quantitatively detected the expression of PTPN14, CNN1, SM22, and GAPDH. The carotid arteries of two mice in the same treatment group were mixed into one independent lane; F. Statistical analysis of immunoblotting of carotid artery proteins PTPN14, CNN1, and SM22. Data are expressed as Mean ± SEM, and statistical differences were analyzed by unpaired two-tailed t-test, *p < 0.05, n = 6.

[0077] Figure 4Specific knockdown of PTPN14 in smooth muscle cells inhibits cell migration and proliferation. A. After knockdown of PTPN14 in human aortic smooth muscle cells, scratch assay was performed and PDGF-BB (20 ng / mL) was given. The migration distance of cells was recorded at 0 and 24 hr, respectively. Scale bar = 20 μm; B. Statistical analysis of cell scratch assay. Data are expressed as Mean ± SEM, and statistical differences were analyzed by two-way ANOVA, *p < 0.05, n = 6; C. After 48 hr of transfection of siRNA in human aortic smooth muscle cells, they migrated through transwell chambers and were induced with PDGF-BB (20 ng / mL) for 6 hr. Cell migration was evaluated by staining of cell nuclei with DAPI. Scale bar = 100 μm; D. Statistical analysis of cell transwell assay. Data are expressed as Mean ± SEM, and statistical differences were analyzed by two-way ANOVA, *p<0.05, n=6; E. Human aortic smooth muscle cells transfected with siRNA were treated with PDGF-BB (20 ng / mL) for 24 hours, and the cells were stained with Ki67 immunofluorescence. Ki67-positive cells: green; cytoskeleton phalloidin staining (marking F-actin): red; cell nucleus DAPI: blue; scale bar = 20 μm; F. Statistical analysis of Ki67 immunofluorescence staining of cells. Data are expressed as Mean ± SEM, and statistical differences were analyzed by two-way ANOVA, *p<0.05, n=6. siNC: control group, siPTPN14: PTPN14 knockout group, siNC+PDGF-BB: control+PDGF-BB treatment group, siPTPN14+PDGF-BB: PTPN14 knockout+PDGF-BB treatment group. DETAILED DESCRIPTION

[0078] The present invention is further described in detail below in conjunction with specific embodiments, and the examples provided are only for illustrating the present invention, rather than for limiting the scope of the present invention. The examples provided below can be used as a guide for further improvements by those of ordinary skill in the art, and do not constitute a limitation of the present invention in any way.

[0079] The experimental methods in the following examples, unless otherwise specified, are all conventional methods, and are performed according to the techniques or conditions described in the literature in the field or according to the product instructions. The materials, reagents, etc. used in the following examples, unless otherwise specified, can all be obtained from commercial channels.

[0080] The quantitative experiments in the following examples were performed in triplicate unless otherwise specified.

[0081] The adenovirus in the following examples has been described in: YANG Y, MA Q, LI Z, et al. Harminealleviates atherogenesis by inhibiting disturbed flowmediated endothelialactivation via protein tyrosine phosphatase PTPN14 and YAP[J]. Br J Pharmacol, 2021, 178(7): 1524-1540. It was designed and synthesized at GeneCare Genetics. The public can obtain the biological material from the applicant, and the biological material is only used for repeating the experiments of the present invention and cannot be used for other purposes.

[0082] The experimental methods in the following embodiments are conventional methods unless otherwise specified. The detailed steps of some experimental methods in the following embodiments are as follows:

[0083] I. Culture and adenovirus infection of human aortic smooth muscle cells

[0084] 1. Culture of human aortic smooth muscle cells

[0085] 1) Human aortic smooth muscle cell line T / G HA-VSMCs (Cat NO.; CRL-1999) were purchased from ATCC (Manassas, VA, USA). When the cells grew to a suitable degree of confluence under a microscope, they were passaged in a biosafety cabinet, which was sterilized with ultraviolet light in advance to ensure a sterile environment;

[0086] 2) Discard the culture medium in the cell dish and wash twice with sterile pre-heated PBS;

[0087] 3) Add an appropriate amount of preheated trypsin for digestion and observe the cell digestion status under a microscope. Depending on the cell shedding condition, digestion can be performed at 37°C. The digestion step can be stopped when the cells appear to be in a single retracted state under the microscope;

[0088] 4) Add DMEM / F12 medium supplemented with FBS (company: Gibco; catalog number: 12400-024) to trypsin-EDTA digestion solution (company: Keygen Biotechnology; catalog number: KGM25200) to terminate digestion, and use a pipette to blow off the cells attached to the bottom of the cell dish;

[0089] 5) Collect the culture medium in a sterile centrifuge tube and centrifuge at 1000 rpm for 5 min at room temperature;

[0090] 6) After centrifugation is complete, gently discard the upper culture medium to avoid losing cells at the bottom of the centrifuge tube;

[0091] 7) Add appropriate amount of DMEM / F12 medium and use a pipette to blow the cell pellet to disperse it into single cells;

[0092] 8) Gently shake the cell dish so that the cells are evenly distributed on the bottom of the dish, and place it in a humidified incubator at 37°C and 5% CO2 for culture. Depending on the cell growth status, cells from passages 4 to 7 are used for cell experiments.

[0093] 2. Adenovirus infection of human aortic smooth muscle cells (using six-well plates as an example)

[0094] 1) Grow cells in a six-well plate to an appropriate degree of confluence and wash twice with preheated PBS;

[0095] 2) Then the medium was replaced with serum-free DMEM, and adenovirus (titer: 1×10 9 PFU / mL), and cells were harvested 48 hr after infection according to the experimental purpose.

[0096] II. Determination of cell migration and proliferation ability

[0097] 1. Cell scratch assay

[0098] 1) After the cells are cultured in a six-well plate and knocked out or overexpressed, the medium is discarded, the plate is washed with PBS, and three parallel straight lines of equal distance are drawn in the circular well, preferably one through the center of the circle;

[0099] 2) Then add PBS to the well to prevent shrinkage of the cells, and use the tip of a sterile 200 μl pipette to draw a line in the well perpendicular to the drawn line, passing through the center of the circle and ensuring that the spacing is consistent as much as possible;

[0100] 3) Wash with PBS several times to remove detached cells, then add serum-free DMEM, and add PDGF-BB (R&D SYSTEMS; Catalog No.: 220-BB) to induce cell migration;

[0101] 4) Record the scratch gap at 0 hr under an inverted microscope, with the magnification of 10×;

[0102] 5) Then, the cells were photographed and their migration distance was recorded at 24 hours after migration. At least three fields of view were photographed for each treatment group at 0 hours and 24 hours, and the experimental results were analyzed using the image processing software ImagePro plus.

[0103] 2 Cell migration assay (Transwell method)

[0104] 1) The chamber used in the Transwell experiment was purchased from BD Falcon, with a pore size of 8.0 μm. The chamber was hydrated before use, placed in a cell well plate, and 100 μl of serum-free DMEM was added to the upper layer and placed in an incubator for hydration;

[0105] 2) The treated cells were digested with trypsin, centrifuged, and resuspended into single cells in 1 mL of serum-free DMEM. The cell digestion method was similar to the smooth muscle cell culture method described above;

[0106] 3) Take 10 μl of cell suspension and count the cells using a cell counting plate. According to the ratio, the number of cells added to the upper chamber is 1.0×10 6 ;

[0107] 4) The culture medium in the chamber was discarded and converted according to the volume of the cell suspension added. The final total volume of the culture medium added to the upper layer was 200 μl, and the culture medium in the lower chamber was 600 μl of serum-free DMEM;

[0108] 5) Gently shake the cell suspension to avoid bubbles in the chamber that affect migration, place it in an incubator for incubation, and terminate migration after 6 hours;

[0109] 6) The culture medium in the upper chamber was discarded, and the chamber was washed with PBS and then inverted on absorbent paper to discard the residual liquid, and then fixed with paraformaldehyde;

[0110] 7) DAPI was used to stain the migrated cell nuclei, and the images were taken under light protection using an inverted fluorescence microscope with a magnification of 10. Five fields of view were randomly selected from the top, bottom, left, and right sides of each treatment group, and the experimental results were analyzed using the image processing software ImagePro plus.

[0111] 3. Cell proliferation assay

[0112] 1) Cell proliferation ability was evaluated by the number of Ki67-positive cells. Cells were passaged in advance and cultured in chambers, and overexpression or transfection was performed according to experimental requirements.

[0113] 2) When the cells grow to an appropriate density, discard the cell culture medium and wash with PBS three times, 5 minutes each time;

[0114] 3) After washing, use paraformaldehyde to fix the cells at room temperature for about 20 minutes;

[0115] 4) Discard the paraformaldehyde and continue washing with PBS for 5 min, 3 times;

[0116] 5) Permeabilize the cells with 0.5% Triton cell permeabilization solution and incubate at room temperature for about 30 minutes;

[0117] 6) Discard the permeabilization solution and then continue to wash with PBS for 5 minutes, 3 times;

[0118] 7) Block the cells with blocking sheep serum and incubate at room temperature for about 30 minutes;

[0119] 8) Prepare the primary antibody in advance, dilute the Ki67 antibody at a ratio of 1:100 with the primary antibody diluent, vortex to mix, add to the chamber for incubation, react overnight at 4°C, and keep away from light during the whole process;

[0120] 9) After incubation, discard the primary antibody mixture in the cells and wash them with PBS three times, 5 minutes each. All subsequent experimental steps need to be carried out in a dark environment;

[0121] 10) Dilute the phalloidin F-actin at a ratio of 1:50, vortex to mix, add to the chamber for incubation to stain the cytoskeleton, and incubate at room temperature for about 30 minutes;

[0122] 11) Then wash with PBS, 5 min, 3 times;

[0123] 12) After removing the border of the chamber, use DAPI to seal the slides to stain the cell nuclei. Place the prepared stained slides in a dark box to keep them moist and store them at 4°C for a short period of time.

[0124] III. Protein extraction and quantification of tissue samples

[0125] 1 Protein extraction from tissue samples (taking the left common carotid artery of mice as an example)

[0126] 1) Combine the two mouse left carotid arteries into one independent sample according to the grouping, put the tissue sample into a grinding tube, and add grinding beads and pre-cooled protein lysis buffer;

[0127] 2) Place the grinding tube in a pre-cooled grinder for grinding, observe the tissue state, and stop grinding when no obvious tissue blocks are seen in the tube;

[0128] 3) The grinding beads in the grinding tube were taken out for low-speed centrifugation, followed by ultrasonic disruption, and then the lysate was centrifuged at 4°C, 12000 rpm, for 10 min;

[0129] 4) Transfer the protein supernatant after centrifugation to a new EP tube and mark it accordingly to avoid aspirating cell debris at the bottom of the tube;

[0130] 5) Take part of the protein for concentration determination, and add 5×SDS to the remaining part according to the volume conversion, vortex mix, and heat in a 100°C metal bath for 10 minutes. The denatured protein can be stably stored at -20°C for a short period of time.

[0131] 2. Protein concentration determination

[0132] The protein concentration determination steps refer to the BCA kit instructions, and the specific operations are as follows:

[0133] 1) Dilute the standard in the kit into 0, 125, 250, 500, 750, 1000, 1500, 2000 according to the concentration ratio;

[0134] 2) Vortex and centrifuge the standard and the protein to be tested and add them to a 96-well plate, 5 μl of solution per well;

[0135] 3) Prepare the detection reagent according to the total amount of standard and protein sample, convert according to the ratio of A solution: B solution = 50:1 and the volume of 200 μl of the mixed solution per well, vortex mix and add to the 96-well plate;

[0136] 4) After incubation at 37°C for 30 min, the protein concentration was measured using an ELISA reader at a wavelength of 562 nm;

[0137] 5) Calculate the volume based on the protein concentration and the required protein loading amount.

[0138] IV. Immunoblotting

[0139] 1SDS-PAGE gel electrophoresis

[0140] Prepare SDS polyacrylamide gel (SDS-PAGE) that matches the protein molecular weight according to the experimental requirements, and ensure that the gel is cross-linked before use.

[0141] 1) Prepare the electrophoresis solution in advance to ensure that it is fully dissolved and then add it to the electrophoresis tank. Fix the PAGE gel with the gel holder that matches the electrophoresis tank, put it into the tank and add the electrophoresis solution to observe whether there is any leakage;

[0142] 2) After ensuring that the positive and negative electrodes of the electrophoresis tank and the gel rack are correctly placed, remove the tooth comb on the upper layer of the PAGE gel and add an appropriate amount of electrophoresis solution;

[0143] 3) Equilibrate the protein and protein marker required for loading at room temperature, vortex mix, and then load the sample according to the converted volume. The protein marker loading volume is 3 μL;

[0144] 4) Make sure the positive and negative poles of the electrophoresis tank and the cover are aligned correctly. Perform electrophoresis at a constant voltage of 70-80V.

[0145] 5) When the sample is compressed by the upper layer of concentrated gel and a clear protein marker band is visible in the lower layer of gel, increase the voltage to 100V and continue electrophoresis;

[0146] 6) Stop electrophoresis when bromophenol blue reaches the bottom of the gel or the desired position.

[0147] 2. Protein transfer, blocking, and antibody incubation

[0148] Protein transfer was performed using the Bio-Rad transfer system using a wet transfer method.

[0149] 1) Prepare the electrotransfer solution in advance and moisten the filter paper and sponge to be used later, and activate the NC membrane with methanol for later use;

[0150] 2) Use the "sandwich" model to transfer the membrane. Place the sponge, filter paper, PAGE gel, NC membrane, filter paper, and sponge on the black plywood corresponding to the negative electrode in the order from bottom to top. Be careful to avoid interference from bubbles. The PAGE gel can be gently pried open with a small plate. Be careful to avoid gel rupture. When placing it, it can be cut as needed. Be careful to avoid direct contact with the protein membrane with your fingers to cause contamination;

[0151] 3) Place the sandwich into the transfer tank. After the positive and negative poles are aligned correctly, use constant current 220V for 120 minutes. During the transfer process, be careful to avoid excessive temperature. Add an ice box to maintain the temperature.

[0152] 4) Prepare the blocking solution in advance, use TBST and skim milk powder to make 5% blocking milk. After the electroporation, wash the protein membrane with TBST and transfer it into the blocking milk for blocking at room temperature for 1 hour;

[0153] 5) Dilute the primary antibody at a ratio of 1:1000 according to the experimental requirements. Wash the blocked protein membrane with TBST to remove the residual milk. Then cut the protein according to the protein marker position, put it into the corresponding antibody dilution solution, and incubate it on a shaker at 4°C overnight.

[0154] 6) The next day, wash the incubated protein membrane with TBST for 10 min, three times;

[0155] 7) Prepare the secondary antibody at a ratio of 1:5000, incubate the protein bands according to the primary antibody, and react for 1 hour at room temperature;

[0156] 8) Wash with TBST for 10 min three times before performing band imaging.

[0157] 3. Protein band imaging

[0158] 1) Prepare the luminescent liquid in the ratio of A liquid: B liquid = 1:1, and pay attention to light protection and timeliness;

[0159] 2) Add an appropriate amount of luminescent liquid droplets to the protein strips and image them using an ECL chemiluminescence instrument;

[0160] 3) Protein bands were analyzed using Image J.

[0161] V Immunofluorescence staining experiment

[0162] 1. Cell immunofluorescence experiment

[0163] 1) The cells were cultured in a chamber, the medium was discarded, and then washed with PBS, fixed with paraformaldehyde, blocked with a membrane, and incubated with a primary antibody. The detailed steps refer to the cell proliferation experiment 1-9 above. If the primary antibody is not conjugated with fluorescence, it is not necessary to protect from light;

[0164] 2) After overnight, wash with PBS at room temperature for 5 min, three times;

[0165] 3) Prepare secondary antibodies labeled with fluorescent groups. Select the corresponding secondary antibodies according to the source of the primary antibody and prepare them at a dilution ratio of 1:200. This step and the subsequent operation steps should be protected from light. Vortex mix and then drop them on the chamber and incubate at room temperature for 1 hour.

[0166] 4) Wash with PBS for 5 min, 3 times;

[0167] 5) After removing the frame around the chamber, wipe off the excess liquid, and seal the slides with DAPI. The stained slides can be placed in a moist dark box and stored at 4°C for a short period of time.

[0168] 2 Immunofluorescence experiment of tissue samples

[0169] 1) Frozen tissue sections stored at -80°C need to be equilibrated at room temperature for 30 minutes, and then washed with PBS for 5 minutes, three times, to remove excess embedding medium OCT;

[0170] 2) Fix with paraformaldehyde at room temperature for 15 min, then wash with PBS for 5 min, three times;

[0171] 3) Use a tissue pen to draw a hydrophobic area around the tissue, add 0.5% Triton X-100 in the circle to permeabilize the membrane, and react at room temperature for 30 minutes;

[0172] 4) Wash with PBS for 5 min, 3 times;

[0173] 5) Add blocking sheep serum for blocking at room temperature and incubate for 30 minutes;

[0174] 6) Dilute the primary antibody at a ratio of 1:200 (PTPN14 was purchased from Santa Cruz, USA, with a catalog number of sc-373766; α-SMA was purchased from Sigma-Aldrich, USA, with a catalog number of A2547; PCNA was purchased from Protein Tech, USA, with a catalog number of 10205-2-AP; α-SMA was purchased from Cell Signaling Technology, USA, with a catalog number of 19245; Ki-67 was purchased from Cell Signaling Technology, USA, with a catalog number of 11882; F-actin was purchased from Cell Signaling Technology, USA, with a catalog number of 12877), vortex mix and centrifuge, discard the blocking solution, directly add the primary antibody, and incubate at 4°C overnight;

[0175] 7) After overnight, the experimental operation refers to the above-mentioned cell immunofluorescence experimental steps.

[0176] VI. Hematoxylin and eosin staining (HE staining) of tissue samples

[0177] 1. After the tissue sections were equilibrated at room temperature for 30 minutes, they were washed with PBS for 5 minutes, three times;

[0178] 2. Fix with paraformaldehyde for 15 min, wash with PBS for 5 min, 3 times;

[0179] 3. Stain with hematoxylin for 2-3 minutes and observe under a microscope until the cell nucleus becomes blue-purple;

[0180] 4. Rinse with tap water for 1 minute to return to blue; react with differentiation solution for 15 minutes, and rinse with tap water;

[0181] 5. Wash away the floating color with differentiation solution for 15 minutes, then rinse with tap water;

[0182] 6. The eosin reaction lasts for 10-15 seconds, and the cell cytoplasm is preferably red under the microscope;

[0183] 7. Soak in 75%, 85%, 95%, 100% (I), and 100% (II) for 5 min respectively for dehydration;

[0184] 8. Place in xylene (I) and xylene (II) for 15 min each for dehydration;

[0185] 9. Seal the slides with neutral gum and place them in a fume hood until they are dry before storing them at room temperature for a long time. Take images using an inverted microscope and analyze the images using ImagePro plus software.

[0186] The statistical analysis methods in the following examples are as follows: Statistical data are expressed as mean ± standard error (Mean ± SEM). The differences between the two groups were compared using the Student's t test. For multiple comparisons, one-way ANOVA and two-way ANOVA were performed using the Bonferroni posthoc test. All statistical analyses were performed using Graphpad Prism 9.0 software. P-value < 0.05 was considered statistically significant.

[0187] Example 1: Study on the role of PTPN14 in vascular remodeling

[0188] 1 Construction of mouse left cervical wire strain model

[0189] 1) 8-week-old C57BL / 6 mice (purchased from Spaifol) were used to construct the endometrial neoplasia model. The mice were anesthetized by intraperitoneal injection of 1.2% tribromoethanol. The mice were then fixed on a simple operating table, the neck was fully exposed and hair was removed, and iodine was used for epidermal disinfection;

[0190] 2) Use surgical scissors to make a midline incision along the mouse neck, and use micro forceps to bluntly separate the connective tissue, adipose tissue, etc. along the left side of the neck until the left common carotid artery is exposed;

[0191] 3) The left common carotid artery and its upstream bifurcations, the internal carotid artery and the external carotid artery, were freed, the superior thyroid artery was freed at the external carotid artery, and a section of 6-0 suture was placed at the distal end above the external carotid artery and ligated to block the blood flow above, and a section of 6-0 suture was placed at the proximal end of the external carotid artery (i.e. below the ligation point and above the bifurcation of the external carotid artery and the superior thyroid artery) without ligation for standby use;

[0192] 4) Use an artery clamp to block the blood flow of the internal carotid artery and the common carotid artery, and use microscissors to cut a small opening in the middle of the area where the external carotid artery is sutured, parallel to the direction of the blood vessel, to allow the guide wire to enter;

[0193] 5) A guide wire with a diameter of 0.38 mm was used to injure the blood vessels. The guide wire entered the common carotid artery through the external carotid artery, and the hemostatic clamp of the common carotid artery was loosened to facilitate the entry of the guide wire. After the guide wire was moved back and forth 5 times, the guide wire was pulled out and the blood flow was clamped with an artery clamp again;

[0194] 6) At this time, the suture placed at the proximal end of the external carotid artery was ligated, the artery clamps of the common carotid artery and the internal carotid artery were loosened, and the state of the blood vessels was observed. After the blood flow was restored, the contralateral blood vessels were only exposed as the control treatment group, and then the neck wound was sutured and disinfected with iodine. Samples were collected 14 days and 21 days after modeling to obtain a mouse left common carotid wire strain model. Different preservation treatments were performed on the blood vessels according to the experimental requirements. HE staining of carotid artery tissue sections (the specific experimental steps are the previous experimental step VI), immunofluorescence staining verification (the specific experimental steps are the previous experimental step V), and protein immunoblotting analysis (the specific experimental steps are the previous experimental step IV).

[0195] The results are as follows Figure 1 As shown: HE staining of carotid artery tissue sections showed that the model was successfully constructed, and the carotid artery vessels showed obvious neointimal growth 14 days and 21 days after surgery; further, immunofluorescence staining revealed that with the increase in the degree of vascular stenosis, the protein expression of PTPN14 in the neointimal region of the vessels also gradually increased ( Figure 1 A and B).

[0196] Western blot analysis was performed on the injured left common carotid artery of mice. The results showed that compared with the control group (the contralateral vessel was only exposed), the expression levels of contractile markers α-SMA and SM22 in the experimental group (smooth muscle cells of the left common carotid guidewire strain model) gradually decreased with the injury days (14 days, 21 days); at the same time, the expression level of PTPN14 also gradually increased ( Figure 1 (C and D) PTPN14 expression is increased in areas of neointimal remodeling that are associated with adverse vascular remodeling, suggesting that it may play a key role in injury-mediated vascular remodeling.

[0197] 2. Virus incubation in the left common carotid artery of mice

[0198] 1) Prepare adenovirus and incubate the matrix gel: F-127 powder (Sigma-Aldrich; Catalog No.: P2443) and physiological saline were prepared into a 30% gel according to the mass volume ratio (for example, 3 g of 10 mL of matrix gel was weighed). F-127 powder was added to 10 mL of normal saline) and fully dissolved in a shaker at 4°C overnight;

[0199] 2) The experimental groups are as follows:

[0200] AdPTPN14 group: Mice were injured by left common carotid wire strain (see step 1 in Example 1 for specific steps). After blood flow was restored, adenovirus matrix gel (16 μL F-127 matrix gel + 4 μL 1×10 9The contralateral right common carotid artery was only exposed without wire injury surgery, and adenovirus matrix gel was applied around the blood vessel (16 μL F-127 matrix gel + 4 μL 1×109 PFU / mL PTPN14 overexpression adenovirus). Note that after the gel and adenovirus are mixed, they should be placed on ice to avoid turning into a gel at room temperature. When the gel turns from liquid to gel around the blood vessel, it can be sutured and disinfected with iodine tincture. The sample was collected after the modeling was completed 14 days later.

[0201] AdNC group: Mice were injured by left common carotid wire strain (for details, see step 1 in Example 1). After blood flow was restored, adenovirus matrix gel (16 μL F-127 matrix gel + 4 μL 1×10 9 PFU / mL control adenovirus); the contralateral right common carotid artery was only exposed without wire injury, and adenovirus matrix gel was applied around the blood vessel (16 μL F-127 matrix gel + 4 μL 1×10 9 PFU / mL control adenovirus) Note that after the gel and adenovirus are mixed, place them on ice to avoid turning into a gel at room temperature. When it changes from liquid to gel around the blood vessels, it can be sutured and disinfected with iodine tincture. The sample can be collected after the modeling is completed after 14 days.

[0202] The results of morphological HE staining showed that compared with the control group AdNC, the degree of vascular intimal hyperplasia in the PTPN14 overexpression AdPTPN14 group was significantly aggravated.

[0203] Immunofluorescence staining was performed on the common carotid arteries of mice, and the number of positive cells for the proliferation marker PCNA was used to measure the difference in cell proliferation ability between different treatment groups. The results showed that after PTPN14 overexpression treatment (AdPTPN14 group), the proportion of PCNA-positive cells in the α-SMA-positive area of ​​the mouse blood vessels increased significantly ( Figure 2 These results suggest that PTPN14 can aggravate the development of neointimal formation.

[0204] Example 2: Specific loss of PTPN14 expression in smooth muscle cells inhibits intimal neogenesis

[0205] 1 Smooth muscle cell PTPN14-specific knockout mice inhibit intimal neogenesis

[0206] To further explore the function of PTPN14 in vascular smooth muscle cells, we crossed the smooth muscle-specific tool mouse Tagln-Cre and PTPN14 flox / flox Mouse, constructed smooth muscle PTPN14 specific knockout mouse PTPN14 SMC- / - .

[0207] Smooth muscle PTPN14-specific knockout mice PTPN14 SMC- / - The construction strategy is as follows:

[0208] PTPN14 flox / - The mouse was constructed by Jicui Pharmaceuticals, with the strain number T020775. The smooth muscle-specific tool mouse Tagln-Cre mouse was obtained from JAX, USA, with the strain number 017491. flox / - Mice were bred to obtain homozygous PTPN14 flox / flox mice; by breeding PTPN14 flox / flox mice and Tagln-Cre mice to obtain smooth muscle PTPN14-specific knockout mice PTPN14 SMC- / - and control mice PTPN14 flox .

[0209] PTPN14 knockout mice SMC- / - A 21-day left common carotid artery guidewire strain model was constructed (see step 1 in Example 1 for specific steps), and then the tissue sections of the common carotid artery were stained with HE. The results showed that compared with the control mice PTPN14 flox , PTPN14 knockout mice SMC- / - Significantly reduced the formation of new intima ( Figure 3 In addition, PCNA immunofluorescence staining was performed on the injured common carotid artery, and the results showed that: SMC- / - In mice, the proportion of PCNA-positive cells was significantly reduced ( Figure 3 C and D).

[0210] Further immunoblotting analysis of the injured blood vessels in mice showed that compared with the control mice, PTPN14 flox Compared with PTPN14 knockout mice SMC- / - The protein expression of CNN1 and SM22 contractile markers increased in the injured arteries ( Figure 3 These results indicate that specific deletion of PTPN14 in smooth muscle cells inhibits the formation of neointima and cell proliferation, reduces the loss of contractile marker protein expression during the phenotypic transformation of smooth muscle cells, and is beneficial for smooth muscle cells to maintain a contractile phenotype.

[0211] 2. Specific knockdown of PTPN14 in smooth muscle cells inhibits cell migration and proliferation

[0212] At the cellular level, siRNA was used to knock down PTPN14 in smooth muscle cells, and PDGF-BB was induced at the same time to explore the effect of PTPN14 knockdown on smooth muscle cell function.

[0213] The steps for culturing smooth muscle cells refer to the above I, Culture of Human Aortic Smooth Muscle Cells.

[0214] The specific experimental steps for siRNA transfection of aortic smooth muscle cells are as follows (taking a six-well plate as an example):

[0215] 1) Grow aortic smooth muscle cells in a six-well plate to an appropriate degree of confluence and wash twice with preheated PBS;

[0216] 2) Add preheated transfection medium optium (company: Gibco, catalog number: 31985-070) into the well plate and place it in a cell culture incubator to pre-incubate the cells for about 20 minutes;

[0217] 3) During this period, the transfection reagent was prepared. The transfection reagent iMAX (company: Thermo Fisher, catalog number: 13778150), control siRNA and target siRNA were respectively added to EP tubes containing 1 mL of optium. The ratio of iMAX to siRNA was 1:1. The control siRNA and target siPTPN14 were purchased from Santa Cruz Biotechnology, where the control siNC catalog number was sc-37007 and the siPTPN14 catalog number was sc-62777.

[0218] 4) After incubation at room temperature for 5 minutes, add the optium mixed with iMAX to the optium mixed with siRNA in proportion and continue incubating at room temperature for 20 minutes. After the incubation is completed, use a pipette to gently beat and mix the transfection reagent mixture;

[0219] 5) Discard the pre-incubated optium in the well plate and gently add the transfection reagent to transfect the cells;

[0220] 6) Observe the cell status. Add serum-free DMEM (company: Gibco; catalog number: 11965092) to cultivate the cells after about 6 hours. The replenishment time can be adjusted according to the cell status. Harvest the cells 48 hours after infection from transfection.

[0221] Figure 4 Here, siNC represents the control group, siPTPN14 represents the PTPN14 knockout group, siNC+PDGF-BB represents the control+PDGF-BB treatment group, and siPTPN14+PDGF-BB represents the PTPN14 knockout+PDGF-BB treatment group. The cell scratch assay and transwell assay in the experimental step II above were used for verification, and the results showed that knocking down PTPN14 attenuated the cell migration induced by PDGF-BB ( Figure 4 AD). Ki67 immunofluorescence staining showed that the intervention of PTPN14 inhibited the proliferation of cells ( Figure 4 E and F).

[0222] This study confirmed that PTPN14 is enriched in smooth muscle cells with neointimal hyperplasia. PTPN14 upregulated its expression level in response to vascular injury in a mouse guidewire strain model. PTPN14 promotes smooth muscle cell migration, proliferation and phenotypic transformation, thereby aggravating the process of intimal hyperplasia. PTPN14 overexpression adenovirus was locally incubated in the injured artery of C57BL / 6 mice. Compared with mice incubated with control adenovirus, PTPN14 overexpression treatment aggravated intimal hyperplasia after injury and promoted cell proliferation; smooth muscle-specific knockout mice PTPN14 SMC- / - The results showed that the area of ​​intimal hyperplasia in mice was reduced and the cell proliferation ability was decreased. This provides strong evidence for the functional specificity of PTPN14 in smooth muscle cells. The intimal layer of the blood vessels was damaged and stripped by wire pulling, so that the smooth muscle cells were directly exposed to PDGF-BB in the blood vessels. This direct effect also proved the role of PTPN14 in smooth muscle cells to a certain extent.

[0223] The present invention has been described in detail above. For those skilled in the art, without departing from the purpose and scope of the present invention, and without the need to carry out unnecessary experimental conditions, the present invention can be implemented in a wide range under equivalent parameters, concentrations and conditions. Although the present invention provides specific embodiments, it should be understood that the present invention can be further improved. In a word, according to the principles of the present invention, the application is intended to include any changes, uses or improvements to the present invention, including departure from the disclosed scope in the application, and changes made with conventional techniques known in the art.

Claims

1. Use of a substance that inhibits PTPN14 gene expression in the preparation of a product for treating or / and preventing vascular intimal hyperplasia.

2. Use of a substance that inhibits PTPN14 gene expression in the preparation of a product that inhibits smooth muscle cell proliferation and / or migration.

3. Use of substances that inhibit the activity of PTPN14 protein in the preparation of products for treating and / or preventing vascular intimal hyperplasia.

4. Use of substances that inhibit the activity of PTPN14 protein in the preparation of products that inhibit smooth muscle cell proliferation and / or migration.

5. Use of a substance that reduces the PTPN14 protein content in the preparation of a product for treating or / and preventing vascular intimal hyperplasia.

6. Use of a substance that reduces the PTPN14 protein content in the preparation of a product for inhibiting smooth muscle cell proliferation and / or migration.

7. The use according to any one of claims 1 to 6, characterized in that: The substance that inhibits PTPN14 gene expression or the substance that inhibits PTPN14 protein activity is any of the following biological materials: 1) a double-stranded RNA molecule, a modified substance thereof, or a pharmaceutically acceptable salt thereof; B1) producing a DNA molecule of the double-stranded RNA molecule described in 1); B2) an expression cassette containing the DNA molecule described in B1); B3) a recombinant vector containing the DNA molecule described in B1); B4) a recombinant vector containing the expression cassette described in B2); B5) a recombinant microorganism containing the DNA molecule described in B1); B6) a recombinant microorganism containing the expression cassette described in B2); B7) a recombinant microorganism containing the recombinant vector described in B3); B8) a recombinant microorganism containing the recombinant vector described in B4); B9) a transgenic animal cell line containing the DNA molecule described in B1); B10) a transgenic animal cell line containing the expression cassette described in B2); B11) a transgenic animal cell line containing the recombinant vector described in B3); B12) a transgenic animal cell line containing the recombinant vector described in B4); B13) A transgenic plant cell line containing the DNA molecule described in B1).

8. The use according to any one of claims 1 to 7, characterized in that: The substance that inhibits PTPN14 gene expression or the substance that inhibits PTPN14 protein activity is a double-stranded RNA molecule, and the double-stranded RNA molecule is siPTPN14 (Santa Cruz Biotechnology Company, catalog number: sc-62777).

9. A product for treating or / and preventing intimal hyperplasia, said product comprising any of the following biological materials: 1) a double-stranded RNA molecule, a modified substance thereof, or a pharmaceutically acceptable salt thereof; B1) producing a DNA molecule of the double-stranded RNA molecule described in 1); B2) an expression cassette containing the DNA molecule described in B1); B3) a recombinant vector containing the DNA molecule described in B1); B4) a recombinant vector containing the expression cassette described in B2); B5) a recombinant microorganism containing the DNA molecule described in B1); B6) a recombinant microorganism containing the expression cassette described in B2); B7) a recombinant microorganism containing the recombinant vector described in B3); B8) a recombinant microorganism containing the recombinant vector described in B4); B9) a transgenic animal cell line containing the DNA molecule described in B1); B10) a transgenic animal cell line containing the expression cassette described in B2); B11) a transgenic animal cell line containing the recombinant vector described in B3); B12) a transgenic animal cell line containing the recombinant vector described in B4); B13) A transgenic plant cell line containing the DNA molecule described in B1).

10. A product for inhibiting smooth muscle cell proliferation and / or migration, the product comprising any one of the following biological materials: 1) a double-stranded RNA molecule, a modification thereof, or a pharmaceutically acceptable salt thereof; B1) producing a DNA molecule of the double-stranded RNA molecule described in 1); B2) an expression cassette containing the DNA molecule described in B1); B3) a recombinant vector containing the DNA molecule described in B1); B4) a recombinant vector containing the expression cassette described in B2); B5) a recombinant microorganism containing the DNA molecule described in B1); B6) a recombinant microorganism containing the expression cassette described in B2); B7) a recombinant microorganism containing the recombinant vector described in B3); B8) a recombinant microorganism containing the recombinant vector described in B4); B9) a transgenic animal cell line containing the DNA molecule described in B1); B10) a transgenic animal cell line containing the expression cassette described in B2); B11) a transgenic animal cell line containing the recombinant vector described in B3); B12) a transgenic animal cell line containing the recombinant vector described in B4); B13) A transgenic plant cell line containing the DNA molecule described in B1).